国际药学与生命科学研究与发展杂志

抽象的

Bioavailability enhancement of poorly water soluble drugs (BCS Class II and IV Drugs) using hot-melt extrusion (HME): The cost effective approach

Devendra Ridhurkar

For orally administered drugs, solubility and permeability is one of the rate-limiting factors to achieve their desired concentration in systemic circulation for pharma¬cological response. Poor solubility of BCS class II and IV drugs is attributable for delay or failure and due to this reason formulation scientist faces a major challenge to develop a formulation with good bioavailability. Enhancement of solubility and bioavailability of poorly soluble drugs can be achieved by amorphous solid dispersions which are prepared by converting the poorly water-soluble crystalline form into a more soluble amorphous form within the polymeric blends. Hot Melt Extrusion (HME) has been widely used to prepare amorphous solid dispersions for the improvement of solubility and dissolution rates of poorly soluble materials. During the melt extrusion process, the dissolution of APIs into the polymer matrix is accelerated under the influence of shear and heat. HME has gained popularity in the pharmaceutical industry as a means of improv¬ing the bioavailability of drugs due to its wide applications, simple pro¬cess and low costs. HME is an efficient technology for producing solid molecular dispersions with considerable advantages including the absence of solvents, few processing steps, and con¬tinuous operation over solvent-based processes such as spray drying and co-precipitation. Also, HME is one of the recommended processes by FDA to encourage move from batch-to-continuous manufacturing. Moreover, it can be used to earn intellectual property and to make the noninfringing strategies for products development with ANDA para IV fillings. Marketed formulations Kaletra® and Onmel® which are prepared by HME technology, are the classical examples.